Table 1.
Clinical and pathological characteristics of 18 patients enrolled in the study
| Dose Level 1+2 (n = 6) | Dose Level 3 (n = 6) | Dose level 4 (N = 6) | p Value | ||
|---|---|---|---|---|---|
| Age | 62.5 (59–74) | 68 (63–71) | 66 (57–74) | 0.533 | |
| Clinical T stage | T2a | 1 | 0 | 2 | 0.485 |
| T2b | 0 | 0 | 0 | ||
| T2c | 2 | 2 | 2 | ||
| T3a | 3 | 4 | 2 | ||
| Biopsy Gleason score | 7 | 0 | 2 | 1 | 0.392 |
| 8 | 2 | 3 | 3 | ||
| 9 | 3 | 1 | 2 | ||
| 10 | 1 | 0 | 0 | ||
| PSA | 13.425 (5.02–26.62) | 13.775 (9.82–16.18) | 19.5 (10.87–33.60) | 0.309 | |
|---|---|---|---|---|---|
| Kattan's nomogram score | 140.5 (124–176) | 140 (118–167) | 137 (122–173) | 0.894 | |
| Pathlogical stage | pT2b | 0 | 0 | 0 | 0.148 |
| pT2c | 1 | 3 | 4 | ||
| pT3a | 0 | 1 | 1 | ||
| pT3b | 5 | 2 | 1 | ||
| Margin+ | 4 | 4 | 4 | 1 | |
| Node+ | 2 | 0 | 0 | 0.085 | |